BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33572358)

  • 1. The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST).
    Rizzo A; Pantaleo MA; Astolfi A; Indio V; Nannini M
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
    Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
    [No Abstract]   [Full Text] [Related]  

  • 3. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
    Smrke A; Gennatas S; Huang P; Jones RL
    Future Oncol; 2020 Aug; 16(22):1639-1646. PubMed ID: 32517495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].
    Sun XF; Gao XD; Yuan W; Sun JY; Fu M; Xue AW; Li H; Shu P; Fang Y; Hou YY; Shen KT; Sun YH; Qin J; Qin XY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):880-887. PubMed ID: 32927513
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
    von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
    BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
    Indio V; Astolfi A; Tarantino G; Urbini M; Patterson J; Nannini M; Saponara M; Gatto L; Santini D; do Valle IF; Castellani G; Remondini D; Fiorentino M; von Mehren M; Brandi G; Biasco G; Heinrich MC; Pantaleo MA
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term response to pimitespib in postoperative recurrent gastrointestinal stromal tumors with PDGFRA D842V mutation: a case report.
    Teranishi R; Takahashi T; Kurokawa Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Nakajima K; Eguchi H; Doki Y
    Surg Case Rep; 2023 Apr; 9(1):54. PubMed ID: 37027098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
    Bauer S; George S; von Mehren M; Heinrich MC
    Front Oncol; 2021; 11():672500. PubMed ID: 34322383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
    Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib.
    Nannini M; Tarantino G; Indio V; Ravegnini G; Astolfi A; Urbini M; De Leo A; Santini D; Ceccarelli C; Gruppioni E; Altimari A; Castellucci P; Fanti S; Di Scioscio V; Saponara M; Gatto L; Pession A; Martelli PL; Casadio R; Pantaleo MA
    Sci Rep; 2019 Feb; 9(1):2172. PubMed ID: 30778083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
    Dewaele B; Wasag B; Cools J; Sciot R; Prenen H; Vandenberghe P; Wozniak A; Schöffski P; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2008 Sep; 14(18):5749-58. PubMed ID: 18794084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
    Indio V; Ravegnini G; Astolfi A; Urbini M; Saponara M; De Leo A; Gruppioni E; Tarantino G; Angelini S; Pession A; Pantaleo MA; Nannini M
    Front Immunol; 2020; 11():851. PubMed ID: 32670260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
    Qi C; Pan F; Li J; Li Y; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
    Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK
    Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
    Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.
    Grunewald S; Klug LR; Mühlenberg T; Lategahn J; Falkenhorst J; Town A; Ehrt C; Wardelmann E; Hartmann W; Schildhaus HU; Treckmann J; Fletcher JA; Jung S; Czodrowski P; Miller S; Schmidt-Kittler O; Rauh D; Heinrich MC; Bauer S
    Cancer Discov; 2021 Jan; 11(1):108-125. PubMed ID: 32972961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report.
    Fan J; Yang M; Huang B; Wang Z; Luo D; Zhang J; Zhang P; Shi H; Li Y; Nie X
    Diagn Pathol; 2020 Jan; 15(1):8. PubMed ID: 32005261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.